Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial
Phase 4
Completed
- Conditions
- Atrial FibrillationHypertension
- Interventions
- Device: AF Suppression Pacing Algorithm
- Registration Number
- NCT00256152
- Lead Sponsor
- Abbott Medical Devices
- Brief Summary
In patients with a standard indication for pacing and no previous history of AF, detection of Atrial High Rate Episodes predicts an increased risk of stroke and systemic embolism.
Overdrive atrial pacing with the AF Suppression algorithm will reduce the risk of symptomatic AF in patients with standard indication for pacing and no previous history of AF.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2580
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AF Suppression ON AF Suppression Pacing Algorithm -
- Primary Outcome Measures
Name Time Method Composite of ischemic stroke & Non-CNS systemic embolism 3 years Symptomatic or Asymptomatic AT documented by ECG 3 years
- Secondary Outcome Measures
Name Time Method Myocardial infarction [MI], Vascular death Composite of stroke, MI or vascular death 3 years
Trial Locations
- Locations (1)
McMaster University
🇨🇦Hamilton, Ontario, Canada